Recognized as a Hungarian R&D Company
EaseJect has been officially certified as a research and development (R&D) enterprise by the National Research, Development and Innovation Office (NKFIH) of Hungary — a significant milestone in our innovation journey.
This recognition:
Strengthens our professional credibility within Hungary’s innovation ecosystem, Builds trust with government institutions and business partners, Provides access to national R&D funding and collaboration opportunities, And accelerates the momentum of our ongoing and future R&D projects, both domestically and internationally.
With this certification, we are committed to contributing even more actively to Hungary’s innovation goals and global competitiveness.
Managing Director Dr. Chae Chang Hun PhD.
2025. July.
Registration no. : NKFIH-01512-1/2025
Signs Strategic Preclinical Research Agreement with Pharminvivo
EaseJect Kft has entered into a strategic preclinical research agreement with Pharminvivo Ltd., a leading Hungarian preclinical research organization.
Through this collaboration, the two companies will jointly conduct in vivo efficacy and safety evaluations of microneedle (MN) technology. Pharminvivo is led by Professor Zsuzsanna Helyes of the University of Pécs, Hungary.
This partnership marks a significant milestone in EaseJect’s development of microneedle platforms for biopharmaceutical applications, establishing a strong foundation for an integrated preclinical-to-clinical research framework within Hungary.
EaseJect aims to accelerate the clinical translation of its microneedle drug delivery technology for next-generation vaccines and therapeutics, and to strengthen its position as a central research hub for microneedle-based biopharmaceutical evaluation in Europe.
2025. October.
EASEJECT
"Microneedle technology has the potential to revolutionize, improving people’s quality of life and promoting health and convenience worldwide"
About
EaseJect
Microneedle - Make A Difference
Microneedle technology has great potential to replace traditional injections in areas such as vaccines, chronic disease management, localized drug delivery, and gene therapies. However, for cases requiring high-dose drugs or emergency drug delivery, traditional injections will remain essential.
In summary, microneedle technology is more likely to act as an innovative tool that enhances patient convenience and addresses the limitations of traditional methods rather than completely replacing them.